에 대한 최신 뉴스 Artelo Biosciences (NASDAQ:ARTL) 주식

ARTELO BIOSCIENCES INC

Artelo Biosciences

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Artelo Biosciences Inc

Artelo Biosciences Inc Warrants (18/06/2024)

Palo Alto Networks Inc. CEO Nikesh Arora revealed insights into SoftBank Group Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) CEO Masayoshi Son&#8216;s risk-taking philosophy during a recent podcast appearance, comparing the Japanese billionaire&#8217;s approach to life to the fictional character Benjamin Button.
What Happened: Speaking on Zerodha co-founder Nikhil Kamath&#8216;s podcast, Arora described how Son, now 67, embodied a reverse-aging mentality between the ages of 50 and 60.
&#8220;He was going, touching everything his mother said don&#8217;t touch,&#8221; Arora said, referencing how most cultures teach risk aversion from childhood.
Arora, who worked alongside Son at SoftBank, characterized the investor as someone who defied conventional wisdom about settling down and minimizing risk. &#8220;Masa&#8217;s the other way around. &#8216;What are we going to do today? Great. All in,'&#8221; Arora explained.
Son&#8217;s aggressive investment strategy has generated both spectacular wins and losses throughout his career. The SoftBank founder struck gold four times with major investments, including Yahoo! Japan, Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), and ARM Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).
However, his risk appetite also led to dramatic volatility, with Son becoming the world&#8217;s richest man briefly before facing near-bankruptcy.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46189133/nikita-bier-the-founder-of-gas-and-tbh-who-once-asked-elon-musk-to-hire-him-as-vp-of-product-at-twitter-has-joined-x-never-give-up">Nikita Bier, The Founder Of Gas And TBH, Who Once Asked Elon Musk To Hire Him As VP Of Product At Twitter, Has Joined X: &#8216;Never Give Up&#8217;</a>
Why It Matters: This high-stakes approach continues today as <a href="https://www.benzinga.com/markets/tech/25/06/46134697/softbanks-masayoshi-son-sets-sights-on-artificial-super-intelligence-domination-with-bets-on-openai-and-ampere-im-all-in">SoftBank positions itself for artificial intelligence dominance</a>. The company has committed $32 billion to OpenAI since 2024, with Son declaring &#8220;I&#8217;m all in on OpenAI&#8221; at the firm&#8217;s annual shareholder meeting in June. 
SoftBank reportedly <a href="https://www.benzinga.com/markets/tech/25/06/46023729/softbanks-masayoshi-son-proposes-1-trillion-robotics-and-ai-hub-in-arizona-with-tsmc">proposed a $1 trillion robotics and AI hub in Arizona</a> alongside Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Son&#8217;s cultural background provides context for his contrarian philosophy. Arora noted how traditional risk management, particularly from mothers warning children against dangerous activities, shapes most people&#8217;s approach to life. Son deliberately rejected this framework, choosing instead to embrace maximum risk in pursuit of transformational opportunities.
The strategy has paid off handsomely despite setbacks. SoftBank&#8217;s Vision Funds have invested in over 400 companies, though <a href="https://www.benzinga.com/markets/equities/24/07/39743441/after-losing-150b-nvidia-opportunity-masayoshi-sons-softbank-acquires-uk-chipmaker-graphcore-in-">the firm notably sold</a> its Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stake in 2019, missing out on gains worth over $150 billion. Son&#8217;s current net worth stands at $38.8 billion according <a href="https://www.forbes.com/profile/masayoshi-son/">to</a> Forbes, making him Japan&#8217;s second-richest person.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46188863/when-kevin-oleary-found-his-mother-was-secretly-an-investing-genius-the-performance-was-extraordinary-and-better-than-most-hedge-funds">When Kevin O&#8217;Leary Found His Mother Was Secretly An Investing Genius: &#8216;The Performance Was Extraordinary&#8217; And Better Than Most Hedge Funds</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: glen photo / Shutterstock.com

Tech

BABA

GOOGL

NVDA

PANW

SFTBY

SoftBank's Masayoshi Son Lived Life Like 'Benjamin Button' — Nikesh Arora Says He Took Every Risk His Mother Warned Him About And Struck Gold With Alibaba, ARM

TD Securities analyst Andrew Charles downgrades Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) from Buy to Hold and lowers the price target from $25 to $15.

News

Downgrades

Price Target

Analyst Ratings

TD Securities Downgrades Sweetgreen to Hold, Lowers Price Target to $15

On Monday, June 30, U.S. markets closed higher, boosted by optimism over trade deals and possible rate cuts. Despite this strong finish, concerns about tariffs and fiscal policy weighed on overall performance. Investors reacted to soft economic data and shifting central bank expectations, while portfolio adjustments and rising bank stocks added momentum. Still, some analysts warned the rally may not last amid mounting economic and policy uncertainty.
In economic data, the Chicago PMI edged down to 40.4 in June from 40.5 in May, below the expected 42.7. Meanwhile, the Dallas Fed&#8217;s business activity index for Texas manufacturing rose to -12.7 from -15.3, signaling a slight improvement despite ongoing contraction.
Most S&amp;P 500 sectors ended higher on Monday, led by tech, financials, and real estate, while energy and consumer discretionary declined.
The Dow rose 0.63% to 44,094.77, the S&amp;P 500 was up 0.52% at 6,204.95, and the Nasdaq gained 0.47% to 20,369.73.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Tuesday, Japan&#8217;s Nikkei 225 closed 1.43% lower at 39,908.00, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.01% at 8,541.10, led by losses in the Industrials, Telecoms Services, and Materials sectors.
India&#8217;s Nifty 50 was up 0.14% at 25,552.05, and the Nifty 500 rose 0.03% to 23,625.30.
China&#8217;s Shanghai Composite was up 0.39% at 3,457.75, and Shanghai Shenzhen CSI 300 rose 0.17% to 3,942.76.
The Hong Kong market was closed for the Hong Kong Special Administrative Region Establishment Day holiday.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 0.52%.
Germany&#8217;s DAX index declined 0.70%.
France&#8217;s CAC 40 fell 0.62%.
U.K.&#8217;s FTSE 100 index traded lower by 0.26%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading lower by 0.17% at $65.00/bbl, and Brent was down 0.16% at $66.63/bbl.
Oil prices held steady as investors weighed expectations of an OPEC+ output hike in August and ongoing trade negotiations.
Natural gas fell 1.30% to $3.411.
Gold traded higher by 1.56% to $3,359.40, Silver rose 1.81% to $36.500, and Copper gained 1.40% to $5.1455.
Gold prices rose on safe-haven demand amid trade uncertainty and a weaker dollar as investors braced for Trump&#8217;s tariff deadline. Broader metal markets also gained on improved sentiment and China data.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures fell 0.13%, the S&amp;P 500 declined 0.24%, and the Nasdaq 100 was down 0.30%.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index declined 0.34% to 96.46, USD/JPY was down 0.78% to 142.91, and USD/AUD slid 0.07% to 1.5185.
The U.S. dollar fell, hit by fiscal concerns, trade uncertainty, and expectations of faster Fed rate cuts. Trump&#8217;s criticism of the Fed added pressure while investors await key U.S. data.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips, Dollar Weakens Further As Tariff Deadline Looms - Global Markets Today While US Slept

Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $22 price target.

Reiteration

STOK

Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target

Lennar Unit Quarterra Group Begins Leasing At Emblem Mill Road In McDonough, GA; Fourth Emblem Community In Atlanta Market

Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) recorded a 224% YoY increase in June deliveries as the Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival delivered 197,189 units in the first half of 2025, exceeding the total units delivered in the entire year in 2024.
What Happened: The automaker delivered 34,611 vehicles in June, marking the 8th consecutive month where Xpeng delivered more than 30,000 units, the company said in an official press release on Tuesday.
Xpeng also delivered a record 103,181 units in Q2 2025, which the company said was a new quarterly record. The automaker said that it had expanded into over 40 countries and regions throughout the globe.
Why It Matters: The statement from Xpeng comes as the company recently received over <a href="https://www.benzinga.com/markets/asia/25/06/45900203/xpeng-receives-10000-pre-orders-in-under-an-hour-for-new-tesla-model-3-rival-report">10,000 pre-orders</a> for its G7 SUV in 46 minutes. The G7 rivals the Tesla Model 3 and retails for around $30,000.&nbsp;
Xpeng recently suggested that its new self-driving chip is <a href="https://www.benzinga.com/markets/tech/25/06/45903304/xpeng-says-its-new-self-driving-chip-is-3x-more-powerful-than-nvidias-will-power-vw-cars">three times more powerful</a> than Nvidia Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). The company also says it is in talks with companies like Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) as Xpeng&#8217;s Turing Chip will power select VW models&#8217; autonomous driving capabilities in China.
Elsewhere, Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) CEO Jim Farley hailed <a href="https://www.benzinga.com/markets/tech/25/07/46187171/ford-ceo-jim-farley-praises-chinese-evs-amid-affordable-ev-platform-plans-its-the-most-humbling-thing">the Chinese EV industry</a> at an event, saying, "It is the most humbling thing" for manufacturers in the West to see Chinese EVs, signaling the growing role of Chinese EV manufacturers in the global auto industry.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/46132552/telsla-model-y-rival-xiaomi-yu7-suv-receives-nearly-300000-orders-in-1-hour-in-china">Tesla Model Y-rival Xiaomi YU7 SUV Receives Nearly 300,000 Orders In 1 Hour In China</a></li>
</ul>
Photo courtesy: THINK A / Shutterstock.com

TSLA

VWAGY

XPEV

Tesla Rival Xpeng Records 224% Surge In June Deliveries: Crosses 2024 Sales Mark In 6 Months

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.
Nasdaq and S&amp;P 500 scaled new highs on Monday. The Donald Trump administration is reportedly lowering its aspirations for comprehensive reciprocal deals. Instead, it is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46188192/trump-administration-reportedly-scales-back-ambitions-for-comprehensive-trade-deals-before-tariff-deadline">favoring narrower agreement</a>s to avoid the reimposition of U.S. tariffs.
According to a Reuters report, the U.S. will resume trade negotiations with Canada immediately after Ottawa <a href="https://www.benzinga.com/markets/tech/25/06/46161429/canada-rescinds-digital-services-tax-after-trump-calls-it-a-blatant-attack-on-america">rescinded its digital services tax</a> targeting U.S. technology firms.
Meanwhile, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions">reported</a> that the European Union is willing to accept a trade arrangement with the U.S. that includes a 10% universal tariff on many of the bloc's exports. However, it wants the U.S. to commit to lower rates on key sectors such as pharmaceuticals, alcohol, semiconductors, and commercial aircraft. 
The 10-year Treasury bond yielded 4.19% and the two-year bond was at 3.70%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 78.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.10%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.23%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.28%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.19%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.15% at $616.92, while the QQQ declined 0.19% to $550.60, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro </a>data.
Cues From Last Session:
U.S. stocks settled higher on Monday, with the S&amp;P 500 hitting another record close, as information technology, financial, and real estate sectors recorded the biggest gains. However, energy and consumer discretionary stocks bucked the overall market trend, closing the session lower.
President Trump signaled openness to extending the July 9 deadline for reinstating reciprocal tariffs, adding that he remained optimistic about reaching key agreements in the coming weeks.
On the economic front, the Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7. The Dallas Fed's general business activity index for Texas manufacturing climbed to a reading of -12.7 in June compared to -15.3 in the previous month.
Hewlett-Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.47%</td>
<td>20,369.73</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.52%</td>
<td>6,204.95</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.63%</td>
<td>44,094.77</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.12%</td>
<td>2,175.04</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Despite signals of a cooling economy and what he describes as a &#8220;too tight&#8221; Federal Reserve policy, economist Jeremy Siegel sees a bullish path ahead for equities, predicting major indexes could climb another &#8220;5%-10%&#8221; before any significant reckoning from tariff hits.
&#8220;FOMO could add another 5%-10% to major indexes before earning a reckoning with any tariff earnings hit,&#8221; he said.
Markets, already notching fresh all-time highs, are benefitting from a confluence of factors, including de-escalated geopolitical tensions and a retreat in oil prices, he explains.
Siegel points to falling bond yields, with the 10-year Treasury in the &#8220;4.25%-4.30% range,&#8221; as a clear sign that the Fed&#8217;s stance remains restrictive. While personal income data has cooled and housing is &#8220;feeling the pinch of too-high interest rates,&#8221; Siegel believes these factors provide &#8220;ample cover&#8221; for the Fed to pivot.
However, he doesn&#8217;t expect a rate cut at the July 30 meeting, anticipating 25-basis point cuts at each of the subsequent three meetings into early 2026.
According to Siegel, corporate America is coping, with companies like Nike beating estimates despite a &#8220;tariff hit.&#8221; The prevailing skepticism among traders, evidenced by an elevated VIX, suggests that &#8220;FOMO could add another 5%-10% to major indexes.&#8221;
This momentum, he states, will be driven by &#8220;squeezed shorts, AI productivity and margin improvements,&#8221; emphasizing that &#8220;AI adoption can drive outsized efficiency gains&#8221; even in less direct plays like small-cap value.
Meanwhile, giving her outlook on Gold, Aksha Kamboj, the executive chairperson of Aspect Global Ventures, said, &#8220;Gold prices appear to have stabilized at lower levels and are gradually moving higher, driven by expectations that the U.S. Federal Reserve may implement deeper interest rate cuts in 2025 than previously forecast.&#8221;
&#8220;Key events such as the upcoming July 9 tariff deadline and this week's jobs data are likely to be major market catalysts. Strong demand from central banks and domestic buyers is expected to provide support to the precious metal,&#8221; she added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>June&#8217;s S&amp;P final U.S. manufacturing PMI will be out by 9:45 a.m., and May&#8217;s construction spending and job openings data will be released by 10:00 a.m. ET.</li>
<li>June&#8217;s ISM manufacturing data will be out by 10:00 a.m., whereas auto sales data will also be released on Tuesday.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>MSC Industrial Direct Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) was up 0.80% in premarket on Tuesday as analysts expect it to report quarterly earnings of $1.03 per share on revenue of $970.23 million before the opening bell.</li>
<li>Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) was 0.037% below the flatline as analysts expect it to report earnings of $3.31 per share on revenue of $2.55 billion, after the closing bell.</li>
<li>Greenbrier Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) was 0.11% higher as analysts expect it to report quarterly earnings of 98 cents per share on revenue of $785.72 million after the closing bell.</li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) tumbled 2.98% after disclosing a proposed public offering of common stock.</li>
<li>Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) slipped 3.71% after posting better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025.</li>
<li>AeroVironment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) declined 4.90% after it announced plans to offer $750 million of common stock and $600 million of convertible senior notes in proposed public offerings.</li>
<li>Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) surged over 80% in premarket after implementing a prepackaged restructuring plan supported by most of its lenders. This move aims to cut its debt by ~$4.6 billion or 70% and annual cash interest payments by ~60%, positioning it for accelerated growth and profitability by late third quarter.</li>
<li>Prestige Wealth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) zoomed 68.09% after divesting its Prestige Assets International Inc. subsidiary and its three units on June 25, to sharpen its focus on technology-driven wealth management.</li>
<li>Bitmine Immersion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) gained 21.33% after announcing a $250 million private placement to launch its Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) Treasury Strategy, aiming to become one of the largest publicly traded ETH holders.</li>
<li>Gibo Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) declined over 7% after testing its AI-driven GIBO Click engine on uDrama, a rapidly growing global short drama platform.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.14% to hover around $65.20 per barrel.
Gold Spot US Dollar rose 1.11% to hover around $3,339.46 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.33% at the 96.5570 level.
Asian markets ended on a mixed note on Tuesday, as Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200 indices declined, and India's S&amp;P BSE Sensex, China&#8217;s CSI 300, and South Korea's Kospi indices rose. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46188237/bill-gates-is-betting-two-thirds-of-his-foundations-portfolio-in-these-3-stocks">Bill Gates Is Betting Two-Thirds Of His Foundation&#8217;s Portfolio In These 3 Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

$ETH

AVAV

BMNR

GIBO

JNPR

NKTR

PRGS

WOLF

US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%…,' Says Expert

TradePulse Alert Confirms Early Rise in HOOD
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30200742/Screenshot-2025-06-30-at-4.05.51%E2%80%AFPM-998x1024.png" alt="" class="wp-image-15106" /></figure>
Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:44 AM on June 30th, a significant trading signal occurred for Robinhood Markets Inc. (HOOD) as it demonstrated a Power Inflow at a price of $87.23. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Robinhood's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Robinhood's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for HOOD,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like<a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025"> https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $87.23. The returns on the High price ($94.13) and Close price ($93.65) after the Power Inflow are respectively 7.9% and 7.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. They were close today but this is not always the case.
Past performance is not indicative of future results

Technicals

Opinion

Signals

Trading Ideas

HOOD

Robinhood Rises 7.9% After Key Trading Signal

ATAI

atai Life Sciences Raises $50M In Private Placement Led By Ferring Ventures, Apeiron; Funds To Support Mental Health Drug Pipeline

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54284529&amp;newsitemid=20250701003239&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=47ff461d295196d8e90bef72765f97e7">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced it is now the first Internet infrastructure provider to block AI crawlers accessing content without permission or compensation, by default. Starting today, website owners can choose if they want AI crawlers to access their content, and decide how AI companies can use it. AI companies can also now clearly state their purpose – if their crawlers are used for training, inference, or search – to help website owners decide which crawlers to allow. Cloudflare's new default setting is the first step toward a more sustainable future for both content creators and AI innovators.
For decades, the Internet has operated on a simple exchange: search engines index content and direct users back to original websites, generating traffic and ad revenue for websites of all sizes. This cycle rewards creators that produce quality content with money and a following, while helping users discover new and relevant information. That model is now broken. AI crawlers collect content like text, articles, and images to generate answers, without sending visitors to the original source – depriving content creators of revenue, and the satisfaction of knowing someone is viewing their content. If the incentive to create original, quality content disappears, society ends up losing, and the future of the Internet is at risk.

Cloudflare Blocks AI Crawlers by Default to Protect Creators and Preserve the Open Web

<a href="https://www.globenewswire.com/Tracker?data=tGz0dw0pR_P89fCX0FX2-gR7RuVgBcSWd46s9xalhYWIklGKuAnK-r-Ohi8VeH5np2Q2ZXOURr8mrEDOC66KWg==">atai Life Sciences</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and <a href="https://www.globenewswire.com/Tracker?data=wW0gyjlj2Y1nMJJXwZPe4EYcRlDWYB_3agsCfQdOeEepSi_1-4Xdko8zwLcguFNvAfFkBqkOtR0p-2DFabXKeQhVvd9gwJgJoRftm7aYxhM=">Beckley Psytech Limited</a>&nbsp;("Beckley Psytech"), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg comparator group (p = 0.0038). For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p=0.0025 for change vs. 0.3 mg control). Notably, both the 8mg and 12mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to Week 8.
Safety and efficacy results from this study support the selection of the 8 mg dose of BPL-003 for advancement into Phase 3 clinical studies. atai and Beckley Psytech plan to engage with the U.S. Food and Drug Administration (FDA) and other applicable agencies regarding the Phase 3 trial design for patients with treatment-resistant depression in the coming months.
With these positive Phase 2b results, the pre-agreed success criteria for the proposed strategic combination between atai and Beckley Psytech, which was <a href="https://www.globenewswire.com/Tracker?data=Lt5j5BhiTtHS91OwzC43YoUVuGJaUtezdgq72Y5stYLZkHr4bb9o577WWVdJxus65y-bxktrE-m2HzVPBckcZGIo9XaRX-W5NvSz-VAyy2x2u4cfn9aY-9bPS0KD2JyxcmZZWJbpb4JuhEW5rVBliZZUWUU5eg5ihDS8sBwsqHvblHLEnC_9lIACrn6IvlSAylV04CEThCH-uPz_ccyGFx5oNBbVUDWGnlC6IVPw-EE=">announced in June 2025,</a> has been achieved and the strategic combination is now expected to progress to atai shareholder approval stage. The atai Beckley combination is expected to create a global leader in short time in-clinic psychedelic-based mental health therapies.
Cosmo Feilding Mellen, Chief Executive Officer and Co-Founder of Beckley Psytech, said: "The achievement of our primary and secondary endpoints in this study represents an important milestone in the development of BPL-003 and reinforces its potential to be a viable treatment option for patients and healthcare systems. We are particularly encouraged that a single 8 mg or 12 mg dose of BPL-003 showed rapid and durable efficacy results, favourable tolerability and a short time in-clinic, giving us important flexibility in optimising the design of future trials. Thank you to all of the patients and study partners who participated in this study - we now look forward to preparing for end-of-Phase 2 meetings with regulators and moving forward with our strategic combination with atai Life Sciences to form atai Beckley, a global leader in psychedelic-based mental health treatments."
The Phase 2b clinical study was conducted at 38 sites across six countries and enrolled a total of 193 patients with moderate-to-severe TRD (defined as non-response to two or more prior treatments in the current depressive episode) (<a href="https://www.globenewswire.com/Tracker?data=kSI-UnKZ0DWeSwYIsB0N090rWka30y2wA4jPYu0nejPg7OVIE6Y9-lDi86fU3j9pns2LTvJDSceDpY7US5Ca9x1v_eZEapoW8PDPBYTLRgoNJwv7P7HNhAmrRG2HXGOJcTrJfssR6lmmu6k1ezzAxw==">NCT05870540</a>). It is the largest controlled clinical study to investigate mebufotenin and the only blinded Phase 2b study of mebufotenin to include the United States. Patients were randomized to receive a single 12 mg (n=73), 8 mg (n=46), or 0.3 mg comparator (n=74) dose of BPL-003 and were followed for eight weeks with efficacy assessments conducted by centralised, blinded raters using the MADRS at Day 2, Day 8, Day 29 and Day 57.
Key efficacy findings:
<ul>
<li>A single 12 mg dose of BPL-003 led to a mean reduction in MADRS score from baseline of 11.1 points compared with 5.8 points in the 0.3 mg comparator arm (p=0.0038) at Day 29, with the 8 mg dose arm showing a mean MADRS reduction from baseline of 12.1 points versus the 0.3mg comparator arm (p=0.0025) at that same timepoint.</li>
<li>The 8 mg and 12 mg doses of BPL-003 demonstrated equivalent efficacy suggesting the 8 mg dose may be sufficient to achieve therapeutic benefit from a single dose.</li>
<li>The difference in MADRS scores between the 8 mg and 12 mg doses versus the 0.3 mg dose were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions from baseline of 8.8 points in the 8 mg group and 8.9 points in the 12 mg group observed at that timepoint, compared to a reduction from baseline of 3.9 points in the 0.3 mg group. These mean reductions from baseline increased to 11.1 points in the 8 mg group and 10.8 points in the 12 mg group at Day 8.</li>
<li>A durable effect was also observed for both higher doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared with the 0.3 mg group (5.2 point reduction). These findings highlight the potential of BPL-003 to be a durable treatment for patients with TRD.</li>
</ul>
Key safety findings:
<ul>
<li>BPL-003 was generally well-tolerated at all doses. More than 99% of treatment-emergent adverse events (TEAEs) were mild or moderate and there were no drug-related serious adverse events (SAEs).</li>
<li>Dose related increases in administration site discomfort, nausea, headache, blood pressure and anxiety suggest the 8mg dose was better tolerated than the 12mg dose.</li>
<li>No participants in the 8 mg nor 12 mg arms had any instance of treatment-emergent suicidal intent or behaviour, indicating no suicide-related safety signal observed to date.</li>
<li>The average time to meet readiness for discharge criteria across all arms was within two hours of dosing, with the majority of patients deemed ready for discharge at the 90 minutes post-dose assessment. This, alongside the administration of BPL-003 via a previously approved nasal spray device, supports the potential of BPL-003 to fit within the existing interventional psychiatry treatment paradigm that has been successfully established by Spravato&#xAE;.</li>
<li>The study had a low drop-out rate with 90% of patients completing the core study.</li>
<li>These findings suggest a favourable tolerability profile which are consistent with earlier Phase 1 and Phase 2a studies of BPL-003, as well as other psychedelic studies within the class.</li>
</ul>
Additional data from the core study is expected to be shared through publications and medical meetings in the future.

Atai and Beckley Report Depression Trial Results, Pave Way for Psychedelic-Based Mental Health Breakthrough

Venture Global's Calcasieu Pass LNG Facility Upgraded To Investment-Grade 'BBB-' By S&P After Commercial Launch, LRT Completion

Amid the turmoil and uncertainties in recent months, U.S. equity markets have reached a staggering new milestone, with market capitalization hitting $63.8 trillion.
What Happened: On Monday, in a post on X, The Kobeissi Letter shared recent data from Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) showcasing the remarkable surge in valuations in the U.S. equity markets over the past five years.
&#8220;This is incredible,&#8221; the post says, adding that the &#8220;U.S. market has never been this large,&#8221; after doubling from under $31 trillion in 2020. 
See Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46166959/sp500-stocks-outlook-etf-analysis">This S&amp;P 500 ETF Saw A 30-Month Buying Spree — Now It&#8217;s Over</a>
For comparison, the post notes that it took eight years, from 2012 to 2020, to double in value during the previous cycle, clearly highlighting the acceleration being witnessed in U.S. equity markets, which comes despite substantial trade, tariffs, and geopolitical uncertainties.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is incredible: The US stock market has never been this large. Total US public equity market capitalization hit a record $63.8 TRILLION, according to Goldman Sachs data. That's DOUBLE the size it was 5 years ago. By comparison, previously it took 8 years, from 2012 to… <a href="https://t.co/q72isq7XV4">pic.twitter.com/q72isq7XV4</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1939838864471773200?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
To further emphasize the magnitude of this milestone, the post says that U.S. markets are now &#8220;three times larger than Europe&#8217;s,&#8221; while being larger than the &#8220;combined market size of Europe, China, Hong Kong, Japan, and India.&#8221;
&#8220;Mind-blowing numbers,&#8221; it says in conclusion.
Why It Matters: The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), touched a fresh intraday high on Monday, hitting 6,215.08 points. 
Leading analysts, such as Ryan Detrick, note that this is the first time since 1950 that the index has hit an all-time high in June.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Stocks just made a new all-time high in June. Stocks have never peaked in June. &#x1f9d0; <a href="https://t.co/ItYm8vmOog">pic.twitter.com/ItYm8vmOog</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1938949133832003645?ref_src=twsrc%5Etfw">June 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, the index flashed a sign that traders refer to as a &#8220;Golden Cross,&#8221; when the 50-day moving average rises above the 200-day moving average, often seen as a sign of momentum picking up and a <a href="https://www.benzinga.com/markets/economic-data/25/06/46124290/sp-500-hits-record-highs-and-history-says-the-best-is-yet-to-come">new high being underway</a>.
Analysts note that since World War 2, the Golden Cross has appeared 37 times, and three out of four times, it has led to gains.
Price Action: The S&amp;P 500 was up 0.52% on Monday, trading at 6,204.95 points, while the Nasdaq ended up 0.47%, at 20,369.73, followed by the Dow Jones at 44,094.77, up 0.63%.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46188576/sp-hits-record-high-at-the-end-of-q2-investor-sentiment-improves-fear-index-remains-in-greed-zone">S&amp;P Hits Record High At The End Of Q2: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo courtesy: Shutterstock

US Stock Market Hits Record $63.8 Trillion, Doubling In 5 Years: Now Bigger Than Europe, China, Japan, India Combined

Two Chinese artificial intelligence chip startups, Moore Threads and MetaX, are planning to raise a combined 12 billion yuan ($1.65 billion) through initial public offerings (IPOs). 
What Happened: The two companies are betting on the U.S. export restrictions to boost the demand for their products in China, Reuters reported. 
Moore Threads, based in Beijing, aims to raise 8 billion yuan, while MetaX, based in Shanghai, is looking to raise 3.9 billion yuan. Both companies are planning to list on the STAR Market, the tech-focused board of the Shanghai Stock Exchange
These fundraising plans highlight the increasing efforts of Chinese chipmakers to capitalize on Beijing&#8217;s drive to develop domestic champions in graphics processing units (GPUs), which are crucial for AI development.
See Also: <a href="https://benzinga.com/markets/tech/25/06/46159877/steve-jobs-once-spent-two-weeks-choosing-a-washing-machine-for-his-palo-alto-home-and-he-got-more-thrill-out-of-it-than-any-piece-of-high-tech-in-ages">Steve Jobs Once Spent Two Weeks Choosing A Washing Machine For His Palo Alto Home And He Got More &#8216;Thrill&#8217; Out Of It Than Any Piece Of High Tech In Ages &#8211; Benzinga</a>
The U.S. has been tightening export restrictions on China, with the latest rules implemented in April banning the shipment of Nvidia&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H20 chips, one of its most popular chips, to China. These restrictions have led to a sense of urgency in Beijing to develop domestic chip champions.
Both Moore Threads and MetaX have cited U.S. sanctions as a major risk to their development, but have also emphasized that the restrictions could create significant market opportunities. The two companies design GPUs to compete with Nvidia products and have reported significant losses over the last three years, largely attributed to heavy research and development spending.
Why It Matters: The move by Moore Threads and MetaX to go public amid U.S. export sanctions is part of a larger trend of Chinese companies seeking to <a href="https://www.benzinga.com/markets/equities/25/03/44350873/nvidia-faces-new-ai-challenge-as-chinese-start-up-unveils-framework-to-cut-reliance-on-its-gpus">reduce their reliance</a> on foreign chipmakers. In May, Alibaba (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), and Tencent (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) began switching to <a href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply">homegrown chips</a> as U.S. export controls and a dwindling stockpile of Nvidia processors eroded their ambitions. 
The move also aligns with China&#8217;s broader push for <a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">self-sufficiency in chips</a>, with major Chinese automakers aiming for 100% domestic chip supply by 2027. This push is being <a href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report">shepherded</a> by China&#8217;s Ministry of Industry and Information Technology, which regularly requires self-assessments of domestic chip adoption rates.
Read Next: <a href="https://benzinga.com/markets/tech/25/06/46186013/mark-zuckerberg-once-predicted-that-this-technology-would-replace-your-phone-a-decade-later-how-far-">Mark Zuckerberg Once Predicted That This Technology Would Replace Your Phone — A Decade Later, How Far Is Meta From Delivering On A &#8216;More Natural&#8217; Future</a>
Photo: Maxx-Studio On Shutterstock

BIDU

TCEHY

Nvidia's Chinese Rivals Look To Cash In On US Tech Ban: Moore Threads, MetaX Plot $1.65 Billion IPO

Investment advisor Ross Gerber criticized Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) board members on Tuesday for remaining silent as President Donald Trump launched a scathing attack on CEO Elon Musk and federal subsidies supporting his company.
What Happened: &#8220;Sadly true and it seems Elon is destined to find out who is more powerful. Not a peep from the Tesla BOD of this absurd attack on the President he enabled,&#8221; wrote Gerber, CEO of Gerber Kawasaki Wealth &amp; Investment Management, on social media platform X.
Gerber&#8217;s comments followed Trump&#8217;s <a href="https://www.benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-more-rocket-launches-satellites-or-electric-car">Truth Social post claiming Musk</a> &#8220;may get more subsidy than any human being in history, by far&#8221; and suggesting &#8220;without subsidies, Elon would probably have to close up shop and head back home to South Africa.&#8221; 
Trump added that eliminating support would mean &#8220;no more Rocket launches, Satellites, or Electric Car Production,&#8221; while the country &#8220;would save a fortune.&#8221;
The president specifically recommended that the Department of Government Efficiency (DOGE), which Musk previously headed, examine billions in subsidies flowing to his companies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sadly true and it seems Elon is destined to find out who is more powerful. Not a peep from the Tesla BOD of this absurd attack on the President he enabled. <a href="https://t.co/8Ae4o39zJD">https://t.co/8Ae4o39zJD</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1939930759348863132?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46189000/palantir-is-building-the-next-aws-says-top-exec-urges-startups-to-build-on-pltr-to-tackle-more-valuable-problems-than-amazon-solved">Palantir Is Building The Next AWS, Says Top Exec: Urges Startups To Build On PLTR To Tackle &#8216;More Valuable&#8217; Problems Than Amazon Solved</a>
Why It Matters: The public feud marks a dramatic reversal between former allies. Musk <a href="https://www.benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-more-rocket-launches-satellites-or-electric-car">reportedly contributed over $250 million to Trump&#8217;s 2024 campaign</a> before departing the administration in June amid disagreements over Trump&#8217;s &#8220;Big Beautiful Bill&#8221; spending package.
Tesla faces <a href="https://www.benzinga.com/markets/tech/25/06/46162850/tesla-sales-in-canada-have-dropped-to-nearly-zero-says-researcher-expects-elon-musk-led-ev-giant-may-report-losses-starting-2026">mounting operational challenges</a> that compound political tensions. Canadian sales plummeted 87% in Quebec during the first quarter of 2025, according to researcher Troy Teslike, who warned the company may report GAAP losses starting in the first quarter of 2026. Tesla continues operating 35 Canadian stores despite near-zero sales.
Gerber has been a vocal Tesla critic, recently dumping over 20,000 shares in <a href="https://www.benzinga.com/25/05/45559223/ross-gerber-weighs-in-on-tesla-amid-elon-musks-five-year-commitment-to-ev-giant-seems-like-elon-mightve-gotten-my-message">the first quarter of 2025</a>. He previously blamed the board for &#8220;negligence&#8221; regarding brand damage from Musk&#8217;s political activities and called for leadership changes.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46188699/goldman-sachs-now-expects-3-fed-rate-cuts-in-2025-amid-weak-jobs-data-modest-trump-tariff-effects">Goldman Sachs Now Expects 3 Fed Rate Cuts In 2025 Amid Weak Jobs Data, Modest Trump Tariff Effects</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

Ross Gerber Says Elon Musk 'Enabled' The President As Trump Slams TSLA CEO Over Subsidies: Calls Out Tesla Board's Silence On 'Absurd Attack'

The Company delivered 24,925 vehicles in June 2025, representing an increase of 17.5% year-over-year. The deliveries consisted of 14,593 vehicles from the Company's premium smart electric vehicle brand NIO, 6,400 vehicles from the Company's family-oriented smart electric vehicle brand ONVO, and 3,932 vehicles from the Company's small smart high-end electric car brand FIREFLY. The Company delivered 72,056 vehicles in the second quarter of 2025, representing an increase of 25.6% year-over-year. Cumulative deliveries reached 785,714 as of June 30, 2025.
NIO's products have been highly recognized in the 2025 J.D. Power studies. The ET5 and ET5T ranked first among mid-size battery electric sedans in the China NEV-IQS study, while the EC6 claimed the top spot in the premium BEV segment in the China NEV-APEAL study. With superior product quality and exceptional user satisfaction, NIO has secured first place in its segment in J.D. Power's quality research for seven consecutive years since 2019.

NIO Delivers 24,925 Vehicles In June, Up 17.5% YoY; Q2 Deliveries Up 25.6% YoY To 72,056 Vehicles

Shares of Thumzup Media Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) rose sharply in today's pre-market trading after the company announced a $6.5 million <a href="https://www.benzinga.com/quote/TZUP">registered direct offering</a>.
Thumzup Media shares jumped 20.4% to $8.45 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) surged 238.7% to $10.60 in pre-market trading after gaining 12% on Monday.</li>
<li>Wolfspeed, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) gained 90.8% to $0.7639 in pre-market trading after the company initiated pre-packaged restructuring process with support of key lenders.</li>
<li>Prestige Wealth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) climbed 64.1% to $0.58 in pre-market trading.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) rose 41.2% to $0.2640 in pre-market trading after falling around 49% on Monday.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) gained 35.6% to $5.17 in pre-market trading after dipping over 5% on Monday.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) gained 14% to $0.89 in pre-market trading after falling 5% on Monday.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) surged 11.2% to $3.29 in pre-market trading after gaining 28% on Monday.</li>
<li>Jyong Biotech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) jumped 10.2% to $9.37 in pre-market trading. Jyong Biotech recently announced the closing of $20 million initial public offering.</li>
<li>BigBear.ai Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NASDAQ">BBAI</a>) gained 6.7% to $7.24 in pre-market trading after climbing over 16% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares tumbled 19.3% to $0.1865 in pre-market trading after jumping 120% on Monday.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) fell 19.1% to $0.0935 in pre-market trading. Globavend and Strawberrynet Cosmetics, on Monday, executed a strategic partnership.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) dipped 18.7% to $4.31 in pre-market trading after jumping 72% on Monday.</li>
<li>RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) dipped 18% to $2.46 in pre-market trading after falling 7% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) declined 17.3% to $1.15 in pre-market trading after gaining around 15% on Monday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) declined 17.2% to $4.20 in pre-market trading. Applied DNA recently conducted a 27% workforce reduction and ceased operations at Applied DNA Clinical Lab.</li>
<li>Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) fell 16.6% to $11.07in pre-market trading. Artelo Biosciences shares jumped 96% on Monday after the company announced data from its first-in-human study for ART26.12.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 14.5% to $2.89 in pre-market trading after gaining 93% on Monday.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares fell 12.9% to $8.30 in pre-market trading after the company announced the pricing of $200.0 million public offering of common stock.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) fell 6.6% to $59.70 in pre-market trading. Progress Software posted better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

APDN

ARBK

ARTL

BBAI

BGLC

DTCK

GNLN

IPDN

MENS

MSPR

OGEN

SYTA

TZUP

Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Macro Economic Events

Econ #s

Economics

Eurozone Consumer Price Index (YoY) Preliminary For June 2.0% Vs. 2.0% Est.; 1.9% Prior

Eurozone Consumer Price Index (MoM) Preliminary For June 0.3% Vs. 0.0% Prior

Eurozone Core Consumer Price Index (YoY) Preliminary For June 2.3% Vs. 2.3% Est.; 2.3% Prior

Earnings

Press Releases

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Health Care

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

General

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside

AMZN

COST

PLUG

PNPNF

SNYR

TSXV:PNPN

WBUY

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Biofrontera

CNS Pharma

Cocrystal Pharma

China Pharma Holding

Evoke Pharma

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

cbdMD

HC Wainwright & Co.

EF Hutton

Ladenburg Thalmann

Screenshot 2024-04-30 at 10.58.41 PM

Biotech

Interview

&#34;Brand New Science&#34; - This Biotech Is Entering Clinical Studies With What It Says Is Novel Science No One Else Has

Comments

Artelo Biosciences

뉴스

에 대한 최신 뉴스 Artelo Biosciences (NASDAQ:ARTL) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌